{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-014833","form_type":"8-K","ticker":"AVTX","cik":"0001534120","company_name":"Avalo Therapeutics, Inc.","filed_at":"2025-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.922023+00:00","generated_at":"2026-05-24T04:55:45.161174+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Avalo Therapeutics appoints Michael Heffernan as Chairman, separating roles from CEO Garry Neil","bullets":["Michael Heffernan appointed Chairman of the Board, effective March 25, 2025; succeeds Dr. Garry Neil who remains CEO and Board member.","Heffernan brings experience building biopharma companies and executing exits; will guide pipeline including AVTX-009 in Phase 2 LOTUS trial for HS.","Company states sufficient capital to achieve potentially transformative data readout from LOTUS trial next year.","Board also approved Amended and Restated Non-Employee Director Compensation Plan to attract and retain qualified directors."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-014833","json":"https://secwatch.observer/filing/0001628280-25-014833.json","markdown":"https://secwatch.observer/filing/0001628280-25-014833.md","text":"https://secwatch.observer/filing/0001628280-25-014833.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534120/000162828025014833/0001628280-25-014833-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534120/000162828025014833/avtx-20250325.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T04:55:45.161174+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f7f71e8045","claim":"Michael Heffernan was appointed as Chairman of the Board at Avalo Therapeutics, Inc..","evidence_excerpt":"On March 25, 2025, the board of directors (the “ Board ”) of Avalo Therapeutics, Inc. (the “ Company ”) appointed Michael Heffernan to the Board, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534120/000162828025014833/0001628280-25-014833-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chairman of the Board"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}